on MEDIAN TECHNOLOGIES (EPA:ALMDT)
Median Technologies: Promising results for the diagnosis of lung cancer
Median Technologies announced that it will share positive results from the first pivotal study of its eyonis™ LCS software at the IASLC World Conference on Lung Cancer 2024, to be held September 7-10 in San Diego, USA.
The AI-based eyonis™ LCS software demonstrated unmatched accuracy (AUC of 0.9041) in detecting and diagnosing lung cancers in low-dose CT scans. The results of this first pivotal study, REALITY, showed significantly high performance.
Results from the second pivotal study, RELIVE, will be reported in the first quarter of 2025. The company expects to obtain marketing authorizations in the United States and Europe in the first half of 2025.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDIAN TECHNOLOGIES news